Broadening the Therapeutic Armamentarium Against Plaque Psoriasis
Podcast 1
Post-Test/Evaluation
Questions marked with a
*
are required
19%
Contact Information
First Name
Last Name
Email Address
Credentials/Degree (MD, DO, RN, etc.)
Date of Participation
Month
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
Day
01
02
03
04
05
06
07
08
09
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
Year
2018
2019
2020
2021
2022
2023
2024
2025
Which of the following is a recently-approved TYK2 inhibitor for psoriasis that was approved
based on strong PASI 75 and PASI 90 data versus apremilast?
Upadacitinib
Deucravacitinib
Bimekizumab
Tofacitinib
A 28-year-old woman presents to her dermatologist with moderate psoriasis (7% body surface
area) on her neck, scalp, arms, and shoulders. When discussing treatment for this patient, which
of the following would be an indicator that a TYK2 inhibitor might be preferred over other
systemic therapies?
She doesn’t want to take medication every day
She would prefer an oral agent over injection
She has mild disease
She has severe hepatic impairment
Start
Powered by
QuestionPro
Loading...
close
drag_indicator
close
Yes
Cancel
Continue
Answer Question
Continue Without Answering
Keep Data
Discard
close